 Eidos Therapeutics NASDAQ:EIDX was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued to investors on Wednesday, Zacks.com reports. The brokerage currently has a 53.00 price target on the stock. Zacks Investment Researchs price objective would suggest a potential upside of 7.44 from the companys previous ... 